Diane Thompson
Nursing at 132 Ter, Overland Park, KS
License number
Colorado 1636003
Issued Date
Oct 1, 2015
Renew Date
Oct 1, 2015
Expiration Date
Sep 30, 2017
Type
Registered Nurse
Address
Address
6210 W 132Nd Ter, Overland Park, KS 66209
Professional information
Inhalant Formulation Containing Sulfoalkyl Ether Cyclodextrin And Corticosteroid Prepared From A Unit Dose Suspension
US Patent:
2007002, Jan 25, 2007
Filed:
Jun 30, 2006
Appl. No.:
11/479937
Inventors:
James Pipkin - Lawrence KS, US
Rupert Zimmerer - Lawrence KS, US
Diane Thompson - Overland Park KS, US
Gerold Mosher - Kansas City MO, US
Rupert Zimmerer - Lawrence KS, US
Diane Thompson - Overland Park KS, US
Gerold Mosher - Kansas City MO, US
International Classification:
A61L 9/04, A61K 39/395, A61K 38/20, A61K 31/47, A61K 31/137
US Classification:
424045000, 424085200, 424131100, 514171000, 514332000, 514310000, 514651000
Abstract:
An inhalable unit dose liquid formulation containing SAE-CD and corticosteroid is provided. The formulation is adapted for administration to a subject by nebulization with any known nebulizer. The formulation can be included in a kit. The formulation is administered as an aqueous solution or concentrated composition. The formulation is employed in an improved nebulization system for administering corticosteroid by inhalation. SAE-CD present in the formulation significantly enhances the chemical stability of corticosteroid, such as budesonide. A method of administering the formulation by inhalation is provided. The formulation can also be administered by conventional nasal delivery apparatus. The formulation is prepared by mixing SAE-CD, in solid or liquid (dissolved) form, with an inhalable suspension-based unit dose formulation.
Inhalant Formulation Containing Sulfoalkyl Ether Cyclodextrin And Corticosteroid
US Patent:
2013005, Mar 7, 2013
Filed:
Aug 15, 2012
Appl. No.:
13/586380
Inventors:
James D. PIPKIN - Lawrence KS, US
Rupert O. Zimmerer - Lawrence KS, US
Diane O. Thompson - Overland Park KS, US
Gerold L. Mosher - Kansas City MO, US
Rupert O. Zimmerer - Lawrence KS, US
Diane O. Thompson - Overland Park KS, US
Gerold L. Mosher - Kansas City MO, US
Assignee:
CyDex Pharmaceuticals, Inc. - Lawrence KS
International Classification:
A61K 31/56, A61P 11/00, A61M 16/14, A61K 31/58
US Classification:
514174, 514169, 514178, 12820414
Abstract:
An inhalable formulation containing SAE-CD and corticosteroid is provided. The formulation is adapted for administration to a subject by nebulization with any known nebulizer. The formulation can be included in a kit. The formulation is administered as an aqueous solution, however, it can be stored as a dry powder, ready-to-use solution, or concentrated composition. The formulation is employed in an improved nebulization system for administering corticosteroid by inhalation. SAE-CD present in the formulation significantly enhances the chemical stability of budesonide. A method of administering the formulation by inhalation is provided. The formulation can also be administered by conventional nasal delivery apparatus.
Inhalant Formulation Containing Sulfoalkyl Ether Gamma-Cyclodextrin And Corticosteroid
US Patent:
2007002, Jan 25, 2007
Filed:
Jun 30, 2006
Appl. No.:
11/479938
Inventors:
James Pipkin - Lawrence KS, US
Rupert Zimmerer - Lawrence KS, US
Diane Thompson - Overland Park KS, US
Gerold Mosher - Kanses City MO, US
Rupert Zimmerer - Lawrence KS, US
Diane Thompson - Overland Park KS, US
Gerold Mosher - Kanses City MO, US
International Classification:
A61K 31/724, A61K 31/573
US Classification:
424400000, 514058000, 514171000
Abstract:
An inhalable formulation containing SAE-γ-CD and corticosteroid is provided. The formulation is adapted for administration to a subject by nebulization with any known nebulizer. The formulation can be included in a kit. The formulation is administered as an aqueous solution, however, it can be stored as a dry powder, ready-to-use solution, or concentrated composition. The formulation is employed in an improved nebulization system for administering corticosteroid by inhalation. SAE-γ-CD present in the formulation significantly enhances the chemical stability of budesonide. A method of administering the formulation by inhalation is provided. The formulation can also be administered by conventional nasal delivery apparatus. The formulation can include one or more additional therapeutic agents for use in combination with the corticosteroid. SAE-γ-CD is especially useful for solubilizing esterified corticosteroids.
Inhalant Formulation Containing Sulfoalkyl Ether Cyclodextrin And Corticosteroid
US Patent:
2011025, Oct 13, 2011
Filed:
Jan 28, 2011
Appl. No.:
13/015959
Inventors:
James D. Pipkin - Lawrence KS, US
Rupert O. Zimmerer - Lawrence KS, US
Diane O. Thompson - Overland Park KS, US
Gerold L. Mosher - Kansas City MO, US
Rupert O. Zimmerer - Lawrence KS, US
Diane O. Thompson - Overland Park KS, US
Gerold L. Mosher - Kansas City MO, US
Assignee:
CyDex Pharmaceuticals, Inc. - Lenexa KS
International Classification:
A61K 31/715, A61M 11/00, A61P 11/00
US Classification:
514 58, 12820023, 12820016
Abstract:
An inhalable formulation containing SAE-CD and corticosteroid is provided. The formulation is adapted for administration to a subject by nebulization with any known nebulizer. The formulation can be included in a kit. The formulation is administered as an aqueous solution, however, it can be stored as a dry powder, ready-to-use solution, or concentrated composition. The formulation is employed in an improved nebulization system for administering corticosteroid by inhalation. SAE-CD present in the formulation significantly enhances the chemical stability of budesonide. A method of administering the formulation by inhalation is provided. The formulation can also be administered by conventional nasal delivery apparatus.
Inhalant Formulation Containing Sulfoalkyl Ether Cyclodextrin And Corticosteroid
US Patent:
2011012, May 26, 2011
Filed:
Oct 14, 2010
Appl. No.:
12/904897
Inventors:
James D. Pipkin - Lawrence KS, US
Rupert O. Zimmerer - Lawrence KS, US
Diane O. Thompson - Overland Park KS, US
Gerold L. Mosher - Kansas City MO, US
Rupert O. Zimmerer - Lawrence KS, US
Diane O. Thompson - Overland Park KS, US
Gerold L. Mosher - Kansas City MO, US
Assignee:
CyDex Pharmaceuticals, Inc. - Lenexa KS
International Classification:
A61K 39/395, A61K 31/58, A61P 11/00
US Classification:
4241301, 514174
Abstract:
An inhalable formulation containing SAE-CD and corticosteroid is provided. The formulation is adapted for administration to a subject by nebulization with any known nebulizer. The formulation can be included in a kit. The formulation is administered as an aqueous solution; however, it can be stored as a dry powder, ready-to-use solution, or concentrated composition. The formulation is employed in an improved nebulization system for administering corticosteroid by inhalation. SAE-CD present in the formulation significantly enhances the chemical stability of budesonide. A method of administering the formulation by inhalation is provided. The formulation can also be administered by conventional nasal delivery apparatus.
Inhalant Formulation Containing Sulfoalkyl Ether Cyclodextrin And Corticosteroid Prepared From A Unit Dose Suspension
US Patent:
2011000, Jan 13, 2011
Filed:
Jul 13, 2010
Appl. No.:
12/835174
Inventors:
James D. Pipkin - Lawrence KS, US
Rupert O. Zimmerer - Lawrence KS, US
Diane O. Thompson - Overland Park KS, US
Gerold L. Mosher - Kansas City MO, US
Rupert O. Zimmerer - Lawrence KS, US
Diane O. Thompson - Overland Park KS, US
Gerold L. Mosher - Kansas City MO, US
Assignee:
CyDex Pharmaceuticals, Inc. - Lenexa KS
International Classification:
A61K 31/724, A61K 39/395, A61P 11/00
US Classification:
4241311, 514 58
Abstract:
An inhalable unit dose liquid formulation containing SAE-CD and corticosteroid is provided. The formulation is adapted for administration to a subject by nebulization with any known nebulizer. The formulation can be included in a kit. The formulation is administered as an aqueous solution or concentrated composition. The formulation is employed in an improved nebulization system for administering corticosteroid by inhalation. SAE-CD present in the formulation significantly enhances the chemical stability of corticosteroid, such as budesonide. A method of administering the formulation by inhalation is provided. The formulation can also be administered by conventional nasal delivery apparatus. The formulation is prepared by mixing SAE-CD, in solid or liquid (dissolved) form, with an inhalable suspension-based unit dose formulation.
Capsules Containing Aqueous Fill Compositions Stabilized With Derivatized Cyclodextrin
US Patent:
7829114, Nov 9, 2010
Filed:
Mar 9, 2005
Appl. No.:
11/076072
Inventors:
Diane O. Thompson - Overland Park KS, US
James D. Pipkin - Lawrence KS, US
Rupert O. Zimmerer - Lawrence KS, US
James D. Pipkin - Lawrence KS, US
Rupert O. Zimmerer - Lawrence KS, US
Assignee:
CyDex Pharmaceuticals, Inc. - Lenexa KS
International Classification:
A61K 9/48, A61K 9/66
US Classification:
424451, 424452, 424455
Abstract:
A capsule containing an aqueous fill composition that comprises water, a derivatized cyclodextrin, such as sulfoalkyl ether cyclodextrin (SAE-CD) or hydroxypropyl cyclodextrin (HPCD), optionally one or more active agents and optionally one or more excipients is stabilized from degradation, erosion, swelling or dissolution of its shell during storage. The derivatized cyclodextrin is present in an amount sufficient to reduce, eliminate or inhibit degradation, erosion, swelling and/or dissolution of the shell by water present in the fill composition. Alternatively, the derivatized cyclodextrin and another shell-stabilizing material together stabilize the shell from degradation, erosion, swelling and/or dissolution by water present in the fill composition. The derivatized cyclodextrin can reduce the water activity of the fill composition.
Formulations Containing Etomidate And A Sulfoalkyl Ether Cyclodextrin
US Patent:
2003005, Mar 20, 2003
Filed:
Mar 19, 2002
Appl. No.:
10/102049
Inventors:
Roger Rajewski - Lawrence KS, US
Michelle McIntosh - Lawrence KS, US
Diane Thompson - Overland Park KS, US
Gerold Mosher - Kansas City MO, US
Michelle McIntosh - Lawrence KS, US
Diane Thompson - Overland Park KS, US
Gerold Mosher - Kansas City MO, US
International Classification:
A61K031/724
US Classification:
514/058000
Abstract:
An injectable formulation of a sedative hypnotic drug, such as the anesthetic drug etomidate, that is pharmaceutically stable, demonstrates a reduced incidence of pain upon injection, and is bioequivalent with currently approved formulations. The formulation of the present invention employs a sulfoalkyl ether cyclodextrin solubilizing and complexing excipient, such as CAPTISOL® cyclodextrin (sulfobutyl ether -cyclodextrin) to form a true aqueous solution. This formulation minimizes the allergic response and microbial contamination issues typically associated with parenteral emulsion formulations. The present formulation also reduces pain on injection as compared to the known organic solvent based formulations containing etomidate. The liquid formulation can be sterile filtered unlike emulsion-type formulations of sedative hypnotics. The liquid formulation can be lyophilized or otherwise dried to yield a solid formulation.
Inhalant Formulation Containing Sulfoalkyl Ether Cyclodextrin And Corticosteroid
US Patent:
2013030, Nov 14, 2013
Filed:
Nov 14, 2012
Appl. No.:
13/676744
Inventors:
Rupert O. ZIMMERER - Lawrence KS, US
Diane O. THOMPSON - Overland Park KS, US
Gerold L. MOSHER - Kansas City MO, US
Diane O. THOMPSON - Overland Park KS, US
Gerold L. MOSHER - Kansas City MO, US
International Classification:
A61K 47/48, A61K 45/06, A61K 31/58
US Classification:
514174, 514171
Abstract:
An inhalable formulation containing SAE-CD and corticosteroid is provided. The formulation is adapted for administration to a subject by nebulization with any known nebulizer. The formulation can be included in a kit. The formulation is administered as an aqueous solution, however, it can be stored as a dry powder, ready-to-use solution, or concentrated composition. The formulation is employed in an improved nebulization system for administering corticosteroid by inhalation. SAE-CD present in the formulation significantly enhances the chemical stability of budesonide. A method of administering the formulation by inhalation is provided. The formulation can also be administered by conventional nasal delivery apparatus.
Inhalant Formulation Containing Sulfoalkyl Ether Cyclodextrin And Corticosteroid
US Patent:
2007002, Jan 25, 2007
Filed:
Jun 30, 2006
Appl. No.:
11/479979
Inventors:
James Pipkin - Lawrence KS, US
Rupert Zimmerer - Lawrence KS, US
Diane Thompson - Overland Park KS, US
Gerold Mosher - Kansas City MO, US
Rupert Zimmerer - Lawrence KS, US
Diane Thompson - Overland Park KS, US
Gerold Mosher - Kansas City MO, US
International Classification:
A61K 31/724, A61K 31/573
US Classification:
424400000, 514058000, 514171000
Abstract:
An inhalable formulation containing SAE-CD and corticosteroid is provided. The formulation is adapted for administration to a subject by nebulization with any known nebulizer. The formulation can be included in a kit. The formulation is administered as an aqueous solution, however, it can be stored as a dry powder, ready-to-use solution, or concentrated composition. The formulation is employed in an improved nebulization system for administering corticosteroid by inhalation. SAE-CD present in the formulation significantly enhances the chemical stability of budesonide. A method of administering the formulation by inhalation is provided. The formulation can also be administered by conventional nasal delivery apparatus.